Hylomorph secures CHF 5.2 million series-B round

The clinical-stage startup aims to minimise post-surgical complications in medical implants. Proceeds from its CHF 5.2 series B investment CHF 0.9 Million non-dilutive funding will support the company in obtaining the FDA and CE mark approval for its product portfolio, beginning with the Hylomate.
Zum Beitrag auf Startupticker

zurück

We use cookies to make our website user-friendly and reliable; this includes measuring performance and reach. Further information can be found in our Privacy Policy.